Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT
Blood, The Journal of the American Society of Hematology, 2012•ashpublications.org
Intracellular mechanism (s) that contribute to promiscuous signaling via oncogenic KIT in
systemic mastocytosis and acute myelogenous leukemia are poorly understood. We show
that SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival in vitro
and myeloproliferative disease (MPD) in vivo. Genetic disruption of SHP2 or treatment of
oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K
inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2 …
systemic mastocytosis and acute myelogenous leukemia are poorly understood. We show
that SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival in vitro
and myeloproliferative disease (MPD) in vivo. Genetic disruption of SHP2 or treatment of
oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K
inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2 …
Abstract
Intracellular mechanism(s) that contribute to promiscuous signaling via oncogenic KIT in systemic mastocytosis and acute myelogenous leukemia are poorly understood. We show that SHP2 phosphatase is essential for oncogenic KIT-induced growth and survival in vitro and myeloproliferative disease (MPD) in vivo. Genetic disruption of SHP2 or treatment of oncogene-bearing cells with a novel SHP2 inhibitor alone or in combination with the PI3K inhibitor corrects MPD by disrupting a protein complex involving p85α, SHP2, and Gab2. Importantly, a single tyrosine at position 719 in oncogenic KIT is sufficient to develop MPD by recruiting p85α, SHP2, and Gab2 complex to oncogenic KIT. Our results demonstrate that SHP2 phosphatase is a druggable target that cooperates with lipid kinases in inducing MPD.
ashpublications.org
